Inventiva Pharma

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40
Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Inventiva Pharma

Bericht door And its gone! »

http://inventivapharma.com/wp-content/u ... 020120.pdf

Nieuwe presentatie januari 2020 staat online.
medaar liked last!
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.



medaar
Forum gebruiker
Forum gebruiker
Berichten: 231
Lid geworden op: 07 mar 2013 23:20
waarderingen: 47
Contacteer:

Re: Inventiva Pharma

Bericht door medaar »

te onthouden Lanifibranor
fast track FDA
voorsprong op de concurrenten,
gedifferentieerd potentieel voor alle functies (Insulinoresistance, Steatosis, Necro-inflammation, Fibrosis) van NASH op een veilige en effectieve manier vergeleken met Ocaliva Elafibranor Cenicriviroc Resmetrion Aramchol
Word verwacht, dit kwartaal naar fase 3
exclusiteit tot 2035 in de EU en US
beursfre liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Inventiva Pharma

Bericht door And its gone! »

Sterke stijging van de laatste weken begint een beetje te stokken.
Ligt al dagen een groot verkooporder op 2.61€ 26.000 stuks 1 verkoper.
Het is tijd voor een pb.
Ik zou graag de pipeline uitgebreid zien.
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Inventiva Pharma

Bericht door And its gone! »

--dubbel--
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Marbull
Forum gebruiker
Forum gebruiker
Berichten: 144
Lid geworden op: 17 sep 2018 16:14
waarderingen: 23
Contacteer:

Re: Inventiva Pharma

Bericht door Marbull »

And its gone! schreef:
24 jan 2020 15:53
Sterke stijging van de laatste weken begint een beetje te stokken.
Ligt al dagen een groot verkooporder op 2.61€ 26.000 stuks 1 verkoper.
Het is tijd voor een pb.
Ik zou graag de pipeline uitgebreid zien.
2,61?? We zitten aan 4,27...
Innate Pharma, Acacia pharma, QG, lysogene

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Inventiva Pharma

Bericht door And its gone! »

4.61 bedoel ik ;)
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Inventiva Pharma

Bericht door And its gone! »

Er mag nog eens nieuws komen :roll:
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 624
Lid geworden op: 30 mei 2018 21:25
waarderingen: 240
Contacteer:

Re: Inventiva Pharma

Bericht door And its gone! »

BRIEF-Inventiva: Positive Results From Phase IIa Clinical Study with Odiparcil in MPS VI
18:35 (03/02) - Bron: Reuters
Feb 3 (Reuters) - Inventiva SA IVAA.PA :
* REG-INVENTIVA SELECTED TO PRESENT THE POSITIVE RESULTS
FROM ITS
PHASE IIA CLINICAL STUDY WITH ODIPARCIL IN MPS VI AT THE 16TH
ANNUAL WORLDSYMPOSIUMTM
* PHASE IIA CLINICAL STUDY RESULTS IN MPS VI ADULT PATIENTS
SHOWED
CAPACITY OF ODIPARCIL TO IMPROVE KEY CLINICAL PARAMETERS SUCH AS
CORNEAL CLOUDING AND CARDIAC AND RESPIRATORY FUNCTIONS
* STUDY ALSO MET ITS SAFETY PRIMARY OBJECTIVE, CONFIRMING
GOOD
SAFETY PROFILE OF ODIPARCIL

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587785110;))
beursfre liked last!
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, TRIL.

Terugnajaren
Forum gebruiker
Forum gebruiker
Berichten: 173
Lid geworden op: 19 jul 2019 13:50
waarderingen: 196
Contacteer:

Re: Inventiva Pharma

Bericht door Terugnajaren »

Voor diegene die dit aandeel minder intensief opvolgt even het PB plaatsen zodat u ziet dat het eigenlijke nieuws er was op 18/12/2019 en het nieuwe bericht gaat over de presentatie van de reeds bekend gemaakte results, wat overigens niets afdoet aan de verdienste van Inventiva.

"Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th Annual WORLDSymposiumTM

• The Phase IIa clinical study results in MPS VI adult patients showed the capacity of odiparcil to improve key clinical parameters such as corneal clouding and cardiac and respiratory functions
• The study also met its safety primary objective, confirming the good safety profile of odiparcil
Daix (France), February 3, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that Dr. Nathalie Guffon (MD, Hôpital Femme-Mère-Enfant, Lyon, France), investigator of the iMProveS (improve MPS treatment) Phase IIa clinical study, will present a poster, entitled “Treatment of mucopolysaccharidosis type VI patients with odiparcil alone or in addition to enzyme replacement therapy: A Phase IIa study”, at the 16th Annual WORLDSymposium™ taking place from February 10 to 13, 2020 at the Hyatt Regency Orlando, Orlando, Florida.
Dr. Nathalie Guffon will present the positive results of the iMProveS Phase IIa clinical study published on December 18, 2019, which showed that odiparcil improved key clinical parameters in several patients such as corneal clouding and cardiac and respiratory functions. In addition, the clinical study met its safety primary objective further supporting the good overall safety profile of odiparcil already observed in previous Phase I and Phase II clinical studies. Based on the iMProveS clinical study results, Inventiva has decided to continue the clinical development of odiparcil for the treatment of MPS VI.
Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, said: “We are very excited by the results of the iMProveS study showing that odiparcil is able to treat hard-to-reach tissues and improve cardiac and respiratory functions. Given that enzyme replacement therapy as current standard of care shows limited efficacy in these organs, we believe that odiparcil could become a reference treatment for MPS VI. We look forward to present our promising results at the upcoming congress and to pursue the clinical development of odiparcil.”
The presentation details are as follows:
Presentation title: “Treatment of mucopolysaccharidosis type VI patients with odiparcil alone or in addition to enzyme replacement therapy: A Phase IIa study” (poster number: LB-17)
Presenter: Dr. Nathalie Guffon
Date: February 12, 2020
Time: 4.30pm - 6.30pm (Eastern Time)
Location: Hyatt Regency Orlando, 9801 International Drive, Orlando, Florida, United States
.......(ingekort)"

Grtz,
Terugnajaren
NewB76 liked last!

Terugnajaren
Forum gebruiker
Forum gebruiker
Berichten: 173
Lid geworden op: 19 jul 2019 13:50
waarderingen: 196
Contacteer:

Re: Inventiva Pharma

Bericht door Terugnajaren »

PB;

Full-Year 2019: Cash position and revenues

• Cash and cash equivalents of €35.8 million1 at December 31, 2019 compared to
€35.3 million at September 30, 2019 and €56.7 million at December 31, 2018
• Significant contribution of AbbVie's clinical milestone payment (€3.5 million) and the 2017 research tax credit (€3.6 million) to the cash position at December 31, 2019
• Receipt of 2018 research tax credit (€4.2 million) in January 2020
• Extension of cash runway to mid Q1 2021 compared to end of Q3 2020 as previously anticipated
• Increase in 2019 revenues reaching €7.0 million1 compared to €3.2 million in 2018

Daix (France) February 5, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today reported its cash position at December 31, 2019 and its 2019 full-year revenues.

Cash position1
At December 31, 2019, Inventiva’s cash and cash equivalents amounted to €35.8 million1, compared to €35.3 million at September 30, 2019 and €56.7 million at December 31, 2018.
In 2019, the Company’s net cash used for operating activities reached - €28.4 million1 compared to - €34.2 million in 2018. This figure includes a €3.5 million milestone payment from AbbVie in December 2019 following the enrollment of the first psoriasis patient in the clinical study underway with ABBV-157, a drug candidate jointly discovered by AbbVie and Inventiva for the treatment of autoimmune diseases. Another contributing factor was the receipt of a €3.6 million payment in respect of the 2017 research tax credit in the fourth quarter. At January 24, 2020, €4.2 million were received in respect of the 2018 research tax credit. R&D expenses, mainly driven by the development of lanifibranor in the treatment of nonalcoholic steatohepatitis (NASH) and odiparcil in the treatment of mucopolysaccharidosis type VI (MPS VI), increased by around 5.0%1 in 2019 compared to 2018.
Net cash from investing activities in 2019 amounted to - €0.9 million1, compared to - €0.4 million in 2018.
Lastly, net cash generated from financing activities in 2019 stood at €8.5 million1 compared to €32.3 million in 2018, which included the proceeds of the private placement in April 2018 amounting to €32.5 million. In 2019, the Company recorded gross proceeds totaling €8.9 million received from leading US and European biotechnology investors through two capital increases in September and October. Its cash position at year-end 2019 should allow the Company to finance all of its operating activities until the middle of the first quarter of 2021, compared to the end of the third quarter 2020 as previously anticipated, which is after the publication of the results of the ongoing NATIVE Phase IIb clinical study with lanifibranor planned for the first half of 2020.

Revenues1
Inventiva's revenues more than doubled in 2019, reaching €7.0 million1, compared to €3.2 million in 2018.
This significant increase is linked firstly, to the €3.5 million milestone payment received from AbbVie in December 2019 following the enrollment of the first psoriasis patient in the clinical study underway with ABBV-157 (vs. €0.8 million in 2018), and secondly, to the payment of €2.6 million received as part of the collaboration with Boehringer Ingelheim (vs. €1.0 million in 2018).
As the Company had fulfilled all its commitments as part of its collaboration with Boehringer Ingelheim, which ended September 30, 2019, all amounts accounted as "contract liabilities" at December 31, 2018, in accordance with IFRS 15 "Revenue from Contracts with Customer", were written back over the period, generating a positive impact of €2.1 million on IFRS revenue at September 30, 2019.
***
Next key milestones
 Presentation of the results of the iMProveS Phase IIa clinical study evaluating odiparcil in the treatment of MPS VI at the 16th Annual WORLDSymposium, Orlando, February 10-13, 2020
 Publication of the results of the NATIVE Phase IIb clinical study evaluating lanifibranor in the treatment of NASH, first-half 2020
Next investor conferences
 Cowen Annual Health Care Conference, Boston, March 2-4, 2020
 One-Stop Shop: Heart, Liver, Renal Healthcare Investor Conference, New York, April 2, 2020
 European SmallCap Event, Paris, April 14-15, 2020
 H.C. Wainwright Conference, London, April 19-21, 2020
 Jefferies Global Healthcare Conference, New York, June 2-4, 2020
Next financial announcement
§ March 10, 2020 (after market close): Publication of 2019 full-year financial results

Grtz,
Terugnajaren
NewB76 liked last!

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen.


Plaats reactie